Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Stuttgart - Delayed Quote EUR

Sangamo Therapeutics Inc (GBY.SG)

Compare
0.9014
-0.0069
(-0.76%)
At close: March 11 at 8:50:34 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
52,291
176,232
111,299
110,701
118,192
Operating Expense
186,512
295,224
312,580
294,038
247,744
Operating Income
-134,221
-118,992
-201,281
-183,337
-129,552
Net Non Operating Interest Income Expense
5,186
11,102
9,432
5,346
8,775
Other Income Expense
-5,817
-155,013
--
--
--
Pretax Income
-134,852
-262,903
-191,849
-177,991
-120,777
Tax Provision
-12
-5,072
429
306
345
Net Income Common Stockholders
-134,840
-257,831
-192,278
-178,286
-120,996
Diluted NI Available to Com Stockholders
-134,840
-257,831
-192,278
-178,286
-120,996
Basic EPS
-0.71
-1.48
-1.25
-1.23
-0.90
Diluted EPS
-0.71
-1.48
-1.25
-1.23
-0.90
Basic Average Shares
193,549.5000
174,444
154,345
144,568
134,449
Diluted Average Shares
193,549.5000
174,444
154,345
144,568
134,449
Total Operating Income as Reported
-140,038
-274,005
-201,281
-183,337
-129,552
Total Expenses
186,512
295,224
312,580
294,038
247,744
Net Income from Continuing & Discontinued Operation
-134,840
-257,831
-192,278
-178,286
-120,996
Normalized Income
-129,023.5176
-105,808.5552
-192,278
-178,286
-120,996
Interest Income
5,186
11,102
9,432
5,346
8,775
Net Interest Income
5,186
11,102
9,432
5,346
8,775
EBIT
-134,221
-118,992
-201,281
-183,337
-129,552
EBITDA
-123,986
-96,800
-180,719
-165,699
-116,183
Reconciled Depreciation
10,235
22,192
20,562
17,638
13,369
Net Income from Continuing Operation Net Minority Interest
-134,840
-257,831
-192,278
-178,286
-120,996
Total Unusual Items Excluding Goodwill
-5,817
-155,013
--
--
--
Total Unusual Items
-5,817
-155,013
--
--
--
Normalized EBITDA
-118,169
58,213
-180,719
-165,699
-116,183
Tax Rate for Calcs
0
0
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-0.5176
-2,990.5552
--
--
--
12/31/2020 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CLLS Cellectis S.A.
1.2500
+2.46%
 
OTLK Outlook Therapeutics, Inc.
1.5000
+6.38%
 
XERS Xeris Biopharma Holdings, Inc.
4.3900
-4.36%
 
ALLO Allogene Therapeutics, Inc.
2.0300
-0.98%
 
NTLA Intellia Therapeutics, Inc.
9.30
-1.69%
 
BLUE bluebird bio, Inc.
3.9600
+0.51%
 
EDIT Editas Medicine, Inc.
1.4700
-5.77%
 
CRSP CRISPR Therapeutics AG
42.37
-2.24%